Elimination of the immunogenicity of therapeutic antibodies

Journal of Immunology

Volumn 162, Issue 6, 1999, Pages 3663-3671

  Gilliland, Lisa K ^a   Walsh, Louise A ^b   Frewin, Mark R ^a   Wise, Matt P ^a   Tone, Masahide ^a   Hale, Geoff ^a   Kioussis, Dimitris ^c   Waldmann, Herman ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; GENETIC RECOMBINATION; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS; BINDING SITES, ANTIBODY; CELL LINE; CRICETINAE; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN VARIABLE REGION; INJECTIONS, INTRAPERITONEAL; LYMPHOCYTE DEPLETION; MICE; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; PROTEIN ENGINEERING; T-LYMPHOCYTES;

EID: 0033559501     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Benjamin, R. J., S. P. Cobbold, M. R. Clark, and H. Waldmann. 1986. Tolerance to rat monoclonal antibodies: implications for serotherapy. J. Exp. Med. 163: 1539.
2. Hale, G., M.-Q. Xia, H. P. Tighe, M. J. S. Dyer and H. Waldmann. 1990. The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:118.
3. Xia, M.-Q., M. Tone, L. Packman, G. Hale, and H. Waldmann. 1991. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur. J Immunol. 21:1677.
4. Treumann, A., M. R. Lifely, P. Schneider, and M. A. J. Ferguson. 1995. Primary structure of CD52. J. Biol. Chem. 270:6088.
5. Xia, M.-Q., G. Hale, M. R. Lifely, M. A. J. Ferguson, D. Campbell, L. Packman, and H. Waldmann. 1993. Structure of the CAMPATH-1 antigen, a glycosylphosphatidyinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J. 293:633.
6. Xia, M.-Q., G. Hale, and H. Waldmann. 1993. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol. 30: 1089.
7. Isaacs, J. D., R. A. Watts, B. L. Hazleman, G. Hale, M. T. Keogan, S. P. Cobbold, and H. Waldmann. 1992. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748.
8. Lockwood, C. M., S. Thiru, J. D. Isaacs, G. Hale, and H. Waldmann. 1993. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet 341:1620.
9. Isaacs, J. D., V. K. Manna, N. Rapson, K. J. Bulpitt, B. L. Hazleman, E. L. Matteson, E. W. St.-Clair, T. J. Schnitzer, and J. M. Johnston. 1996. CAMPATH-1H in rheumatoid arthritis: an intravenous dose-ranging study. Br. J. Rheumatol. 35:231.
10. Weinblatt, M. E. P. J. Maddison, K. J. Bulpitt, B. L. Hazleman, M. B. Urowitz, R. D. Sturrock, J. S. Coblyn, A. L. Maier, W. R. Spreen, and V. K. Manna. 1995. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum. 38:1589.
11. Isaacs, J. D. 1990. The antiglobulin response to therapeutic antibodies. Semin. Immunol. 2:449.
12. Isaacs, J. D., and H. Waldmann. 1994. Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. Ther. Immunol. 1:303.
13. Weigle, W. O. 1973. Immunological unresponsiveness. Adv. Immunol. 16:61.
14. Weigle, W. O. 1980. Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis. Adv. Immunol. 30:159.
15. Chiller, J. M., G. S. Habicht, and W. O. Weigle. 1970. Cellular sites of immunologic unresponsiveness. Proc. Natl. Acad. Sci. USA 65:551.
16. Chiller, J. M., G. S. Habicht, and W. O. Weigle. 1971. Kinetic differences in unresponsiveness of thymus and bone marrow cells. Science 171:813.
17. 2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93:5512.
18. Ghetie, V., J. G. Hubbard, J.-K. Kim, M.-F. Tsen, Y. Lee, and E. S. Ward. 1996. Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice. Eur. J. Immunol. 26:690.
19. Vaughan, T. J., J. K. Osbourn, and P. R. Tempest. 1998. Human antibodies by design. Nat. Biotechnol. 16:535.
20. Bruggemann, M., and M. J. Taussig. 1997. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol. 8:455.
21. Cox, J. P. L., I. M. Tomlinson, and G. Winter. 1994. A directory of human germ-line Vκ genes reveals a strong bias in their usage. Eur. J. Immunol. 24: 827.
22. Cook, G. P., and I. M. Tomlinson. 1995. The human immunoglobulin VH repertoire. Immunol. Today 16:237.
23. Williams, S. C., J.-P. Frippiat, I. M. Tomlinson, O. Ignatovich, M.-P. Lefranc, and G. Winter. 1996. Sequence and evolution of the human germline Vλ repertoire. J. Mol. Biol. 264:220.
24. Clackson, T., H. R. Hoogenboom, A. D. Griffiths, and G. Winter. 1991. Making antibody fragments using phage display libraries. Nature 352:624.
25. Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. Nature 332:323.
26. Hoogenboom, H. R., A. D. Griffiths, K. S. Johnson, D. J. Chiswell, P. Hudson, and G. Winter. 1991. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 19:4133.
27. Saul, F. A., L. M. Amzel, and R. J. Poljak. 1978. Preliminary refinement and structural analysis of the Fab fragment from human immunoglobulin NEW at 2.0 A resolution. J. Biol. Chem. 253:585.
28. Epp, O., P. Colman, H. Fehlhammer, W. Bode, M. Schiffer, R. Huber, and W. Palm. 1974. Crystal and molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI. Eur. J. Biochem. 45:513.
29. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61.
30. Gunning, P., J. Leavitt, C. Muscat, S.-Y. Ng, and L. Kedes. 1987. A human β-actin expression vector system directs high-level accumulation of antisense transcripts. Proc. Natl. Acad. Sci. USA 84:4831.
31. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequences of Proteins of Immunological Interest, 5th Ed. U.S. Department of Health and Human Services. Washington, DC.
32. Page, M. J., and M. A. Sydenham. 1991. High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology 9:64.
33. Lang, G., D. Wotton, M. J. Owen, W. A. Sewell, M. H. Brown, D. Y. Mason, M. J. Crumpton, and D. Kioussis. 1988. The structure of the human CD2 gene and its expression in transgenic mice. EMBO J. 7:1675.
34. Greaves, D. R., F. D. Wilson, C. Lang, and D. Kioussis. 1989. Human CD2 3′-flanking sequences confer high-level. T-cell specific, position-independent gene expression in transgenic mice. Cell 56:979.
35. Searle, S. J., J. T. Pedersen, A. H. Henry, D. M. Webster, and A. R. Rees. 1995. Antibody structure and function. In Antibody Engineering, 2nd Ed. C. A. K. Borrebaeck, ed. Oxford University Press, Oxford, UK, p. 3.
36. McCafferty, J., A. D. Griffiths, G. Winter, and D. J. Chiswell. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552.
37. Chang, C.N., N. F. Landolfi, and C. Queen. 1991. Expression of antibody Fab domains on bacteriophage surfaces: potential use for antibody selection. J. Immunol. 147:3610.
38. Chothia, C., and A. M. Lesk. 1987. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196:901.
39. Gorman, S. D., M. R. Clark, E. G. Routledge, S. P. Cobbold, and H. Waldmann. 1991. Reshaping a therapeutic CD4 antibody. Proc. Natl. Acad Sci. USA 88: 4181.
40. Dresser, D. W. 1962. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 5:378.
41. Mitchison, N. A. 1964. Induction of immunological paralysis in two zones of dosage. Proc. R. Soc. Lond. Ser. B Biol. Sci. 161:275.
42. Dietrich, F. M., and W. O. Weigle. 1964. Immunological unresponsiveness to heterologous serum proteins induced in adult mice and transfer of the unresponsive state J. Immunol. 92:167-172.
43. Gahring, L. C., and W. O. Weigle. 1989. The induction of peripheral T cell unresponsiveness in adult mice by monomeric human γ-globulin. J. Immunol. 143:2094.
44. Jonker, M., and F. J. Nooij. 1987. The internal image-like anti-idiotypic response to a CD3-specific monoclonal antibody in primates is dependent on the T-cell-binding properties of the injected antibody. Eur. J. Immunol. 17:1519
45. Bajorath, J., and J. Novotny. 1995. Model building of antibody combining sites. Ther. Immunol. 2:95.
46. Cheetham, G. M. T., Hale, G., Waldmann, H., and Bloomer, A. C. 1998. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab and its humanized counterpart. J. Mol. Biol. 284:85.
47. Mian, I. S., Bradwell, A. R., and Olson, A. R. 1991. Structure, function and properties of antibody binding sites. J. Mol. Biol. 217:133.
48. Braden, B. C., and R. J. Poljak. 1995. Structural features of the reactions between antibodies and protein antigens. FASEB J. 9:9.
49. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DRI. Nature 364:33.
50. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685.
51. Sharipo, A., M. Imreh, A. Leonchiks, S. Imreh, and M. G. Masucci. 1998. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated IκBα with the proteosome: a new mechanism for selective inhibition of proteolysis. Nat. Med. 4:939.
52. Fairchild, P. J. 1997. Altered peptide ligands: prospects for immune intervention in autoimmune disease. Eur. J. Immunogenet. 24:155.
53. Sloan-Lancaster, J., and P. M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1.
54. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363:156.
55. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1994. Th2 cell clonal anergy as a consequence of partial activation. J. Exp. Med. 180:1195.
56. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B. Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peplides. Cell 74:197.
57. Hammer, J. 1995. New methods to predict MHC-binding sequences within protein antigens. Curr. Opin. Immunol. 7:261.
58. Sette, A., S. Buus, E. Appella, J. A. Smith, R. Chesnut, C. Miles, S. M. Colon, and H. M. Grey. 1989. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc. Natl. Acad. Sci. USA 86:3296.
59. Whitmer, K. J., Romball, C. G., and Weigle, W. O. 1997. Induction of tolerance to human γ-globulin in FcRγ- and FcγRII-deficient mice. J. Immunol. 159:644.
60. Phillips, J. A., Romball, C. G., Hobbs, M. V., Ernst, D. N., Shultz, L., and Weigle, W. O. 1996. CD4+ T cell activation and tolerance induction in B cell knockout mice. J. Exp. Med. 183:1339.
61. Scully, R., S. Qin, S. Cobbold, and H. Waldmann. 1994. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. Eur. J. Immunol. 24:2383.
62. Spiegelberg, H. L., and W. O. Weigle. 1965. The catabolism of homologous and heterologous 7S gamma globulin fragments. J. Exp. Med. 121:323.
63. Zuckier, L. S., L. D. Rodriguez, and M. D. Scharff. 1989. Immunologic and pharmacologic concepts of monoclonal antibodies. Semin. Nucl. Med. 19:166.